RecruitingPhase 1NCT07523711

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

A Phase 1, Open-label Study to Assess the Effect of Maridebart Cafraglutide (AMG 133) on the Pharmacokinetics of Oral Contraceptives in Postmenopausal Female Participants Living With Overweight or Obesity

Sponsor

Amgen

Enrollment

45 participants

Start Date

Apr 9, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity Overweight

Summary

The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.

Eligibility

Sex: FEMALEMin Age: 45 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called COC and a drug called Maridebart Cafraglutide for people with obesity and overweight. The study is currently recruiting participants at 3 locations. People eligible for this study include women aged 45 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.